Noxafil :: Schering-Plough’s Noxafil fights deadly fungal infections

A new drug, Schering-Plough’s Noxafil, prevents fungal infections better than existing medications among high-risk patients and also seems to have fewer side effects.

Each year more than 1.3 million hospital patients are affected by Invasive Fungal Infections (IFIs). Once these infections are established in high-risk patients, such as stem cell transplant recipients or chemotherapy patients, they are extremely difficult to treat and are often fatal.

According to two landmark studies published recently in The New England Journal of Medicine, Noxafil ? a potent new agent to prevent life-threatening IFIs — significantly reduced the number of deaths due to fungal infections compared to other antifungals. Noxafil is the first and only antifungal approved to prevent the two most common types of IFIs.

Leave a Comment